[Development of anti-cancer drugs based on molecular targeting and their application to brain tumor therapy].
Shiraishi
Tetsuya
T
Department of Neurosurgery, Saga Medical School, 5-1-1 Nabeshima, Saga 849-8501, Japan.
Tabuchi
Kazuo
K
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology; D001932:Brain Neoplasms / Q000188:drug therapy*; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D015398:Signal Transduction / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D018797:Cell Cycle Proteins; D018841:HSP90 Heat-Shock Proteins; D009363:Neoplasm Proteins